TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer

Annals of Oncology - United Kingdom
doi 10.1016/j.annonc.2020.01.013

Related search